Novel pharmacological therapies for irritable bowel syndrome

References

• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
   PubMed Web of Science ®Google Scholar
• Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005 Jun;34(2):189–204.
   PubMed Web of Science ®Google Scholar
• Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023–1034.
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol. 2003 Mar;98(3):600–607.
   PubMed Web of Science ®Google Scholar
• Corsetti M, Caenepeel P, Fischler B, et al. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004 Jun;99(6):1152–1159.
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002 Apr;122(4):1140–1156.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000 Sep;119(3):654–660.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775–85.
   PubMed Web of Science ®Google Scholar
• El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012 Oct 7;18(37):5151–5163.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. Task force on the management of functional bowel disorders. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109(Suppl 1):S2–26.
   PubMed Web of Science ®Google Scholar
• Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1285–1292.
   PubMed Web of Science ®Google Scholar
• Clavé P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011 Aug;34(4):432–442.
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Bmj. 2008;337:a2313.
   PubMed Web of Science ®Google Scholar
• Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013 Sep;108(9):1508–1515.
   PubMed Web of Science ®Google Scholar
• Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80.
   PubMedGoogle Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014 Sep;109(9):1350–1365.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19–31.
   PubMed Web of Science ®Google Scholar
• Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55:1095–1103.
   PubMed Web of Science ®Google Scholar
• Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011;130:71–82.
   PubMed Web of Science ®Google Scholar
• Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344:196–206.
   PubMed Web of Science ®Google Scholar
• Corsetti M, Tack J. New pharmacological treatment options for chronic constipation. Expert Opin Pharmacother. 2014 May;15(7):927–941.
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–1724.
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–1712.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013;37:49–61.
   PubMed Web of Science ®Google Scholar
• Rao SS, Quigley EM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2014 Apr;12(4):616–623.
   PubMed Web of Science ®Google Scholar
• Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1084–1092.
   PubMed Web of Science ®Google Scholar
• Berntgen M, Enzmann H, Schabel E, et al. Linaclotide for treatment of irritable bowel syndrome-The view of European regulators. Dig Liver Dis. 2013 Sep;45(9):724–726.
   PubMedGoogle Scholar
• Bijvelds MJ, Bot AG, Escher JC, et al. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009 Sep;137(3):976–985.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329–341.
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012 Mar;35(5):587–599.
   PubMed Web of Science ®Google Scholar
• Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012 Sep;11(5):841–850.
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58:2580–2586.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov NCT01429987, NCT01919697, NCT01722318
   Google Scholar
• Miner PB, Surowitz R, Fogel R, et al. Plecanatide, a novel Guanylate Cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with Chronic Idiopathic Constipation (CIC): results from a 951 patient, 12 week, multi-center trial. Gastroenterology. 2014;144(5):S–163.
   Google Scholar
• Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–365.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al., A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, et al., Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
   PubMed Web of Science ®Google Scholar
• Tack J, Quigley E, Camilleri M, et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterol J. 2013 Feb;1(1):48–59.
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014 Aug;26(8):1079–1086.
   PubMed Web of Science ®Google Scholar
• Carbone F, Rotondo A, Andrews C, et al. A controlled cross-over trial shows benefit of prucalopride for symptoms control and gastric emptying in gastroparesis. UEG Journal. 2015;3:OP 054.
   Google Scholar
• Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60:209–218.
   PubMed Web of Science ®Google Scholar
• Choi CH, Kwon JG, Kim SK, et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27:705–716.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Watanabe S, Tana C, et al. Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011;23(8):754–e332.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov NCT01895543, NCT01827592, NCT01833065.
   Google Scholar
• Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010 Nov;139(5):1549–1558.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000 Mar 25;355(9209):1035–1040.
   PubMed Web of Science ®Google Scholar
• Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013 Sep;6(5):344–357.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Krause R, Deveze S, et al. Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel symdrome with diarrhea. Am J Gastroenterol. 2014;109(Suppl 2):S535.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014 Jun;12(6):953–959.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150(2):358–366.
   Google Scholar
• Min YW, Rhee P-L. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 2015 May;8(3):136–142.
   PubMed Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014 Oct;63(10):1617–1625.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al., TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22–32.
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov NCT01543178.
   Google Scholar
• Cash BD, Lacy BE, Rao T, et al. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother. 2015;8:1–12.
   Web of Science ®Google Scholar
• Garnock-Jones KP. Eluxadoline: first global approval. Drugs. 2015 Jul;75(11):1305–1310.
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242–253.
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, Annese V, et al. Randomised controlled trial of mesalazine in IBS. Gut. 2016;65(1):82–90.
   Google Scholar
• Lam C, Tan W, Leighton M, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut. 2016;65(1):91–99.
   Google Scholar
• Aziz I, Kurien M, Sanders DS, et al. Screening for bile acid diarrhoea in suspected irritable bowel syndrome. Gut. 2015 May;64(5):851.
   PubMed Web of Science ®Google Scholar
• Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010 Feb;8(2):159–165.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Mar;41(5):438–448.
   PubMed Web of Science ®Google Scholar
• Corsetti M, Akyuz F, Tack J. Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. Neurogastroenterol Motil. 2015 Oct;27(10):1354–1370.
   PubMed Web of Science ®Google Scholar
• Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010 Sep;59(9):1213–1221.
   PubMed Web of Science ®Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016 Jan 2. pii: S0016-5085(15)01862-4. www.clinicaltrials.gov NCT01908465
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ma J, Lin X, et al. Structure-based discovery of novel and selective 5-hydroxytryptamine 2B receptor antagonists for the treatment of irritable bowel syndrome. J Med Chem. 2016;59:707–720.
   PubMed Web of Science ®Google Scholar
• O’Mahony SM, Bulmer DC, Coelho A-M, et al. 5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol Motil. 2010;22:573–578, e124.
   PubMed Web of Science ®Google Scholar
• Ohashi-Doi K, Himaki D, Nagao K, et al. A selective, high affinity 5-HT 2B receptor antagonist inhibits visceral hypersensitivity in rats. Neurogastroenterol Motil. 2010;22:e69–76.
   Google Scholar
• Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012;24:358–e169.
   PubMed Web of Science ®Google Scholar
• Fichna J, Sibaev A, Sałaga M, et al. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil. 2013;25:e550–559.
   PubMed Web of Science ®Google Scholar
• Fichna J, Wood JT, Papanastasiou M, et al. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS One. 2013;8:e85073.
   PubMed Web of Science ®Google Scholar
• Feng -C-C, Yan X-J, Chen X, et al. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. Pain. 2014;155:1591–1604.
   PubMed Web of Science ®Google Scholar